DescriptionShort-term antidepressant efficacy of esketamine versus placebo added to an existing oral antidepressant in people with depression.png
English: Change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score from baseline with addition of esketamine nasal spray (56 or 84 mg) added to an existing oral antidepressant versus placebo nasal spray added to an existing oral antidepressant over 4 weeks in people with treatment-resistant depression.
to share – to copy, distribute and transmit the work
to remix – to adapt the work
Under the following conditions:
attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the
same or compatible license as the original.